Effect of metabolic abnormalities on cognitive performance and clinical symptoms in schizophrenia

Archives of Psychiatry and Psychotherapy

Volumn 15, Issue 4, 2013, Pages 13-25

  Wysokiński, Adam ^a   Dzienniak, Małgorzata ^a   Kłoszewska, Iwona ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cognitive functions; Metabolic syndrome; Obesity; Schizophrenia

Indexed keywords

CLOZAPINE; GLUCOSE; LIPID; LOW DENSITY LIPOPROTEIN; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; ATTENTION; BLOOD PRESSURE; BODY MASS; CALGARY DEPRESSION SCALE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; COMORBIDITY; CONTINUOUS PERFORMANCE TEST; DYSLIPIDEMIA; EXECUTIVE FUNCTION; FEMALE; FINGER TAPPING TEST; GLUCOSE BLOOD LEVEL; HUMAN; LEARNING AND MEMORY TEST; MALE; METABOLIC DISORDER; OBESITY; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PSYCHOLOGIC TEST; REACTION TIME; SHIFTING ATTENTION TEST; SIMPSON-ANGUS SCALE; STROOP TEST; SYMBOL DIGIT CODING; VERBAL MEMORY; VERBAL MEMORY TEST; VISUAL MEMORY; VISUAL MEMORY TEST; VITAL SIGN;

EID: 84893975613     PISSN: 15092046     EISSN: None     Source Type: Journal    
DOI: 10.12740/APP/19967     Document Type: Article

References (21)

1. De Hert MA, Van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83:87-93.
2. Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr. 2007;29:330-336.
3. McIntyre RS, Park KY, Law CW et al. The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs. 2010;24:741-753.
4. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry. 2006;67:575-583.
5. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469-480.
6. Grundy SM, Brewer HBJ, Cleeman JI, Smith SCJ, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.
7. Kowalski J, Barylski M, Godala M, Irzmański R, Brocka E, Pawlicki L. Estimation of cardiovascular complications and death risk in subjects with metabolic syndrome. Arch Med Sci. 2006;2:252-255.
8. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 2000;26:119-136.
9. Hill SK, Schuepbach D, Herbener ES, Keshavan MS, Sweeney JA. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naive patients with schizophrenia. Schizophr Res. 2004;68:49-63.
10. Snitz BE, Macdonald AW, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull. 2006;32:179-194.
11. Arango C, Bobes J, Kirkpatrick B, Garcia-Garcia M, Rejas J. Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: findings from the CLAMORS study. Eur Neuropsychopharmacol. 2011;21:867-875.
12. Rummel-Kluge C, Komossa K, Schwarz S et al. Head-tohead comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123:225-233.
13. Yim CY, Soczynska JK, Kennedy SH, Woldeyohannes HO, Brietzke E, McIntyre RS. The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. Eur Psychiatry. 2012;27:223-228.
14. Birns J, Morris R, Jarosz J, Markus HS, Kalra L. Hypertension-related cognitive decline: is the time right for intervention studies? Minerva Cardioangiol. 2009;57:813-830.
15. Zuccala G, Onder G, Pedone C, Carosella L, Pahor M, Bernabei R, Cocchi A. Hypotension and cognitive impairment: Selective association in patients with heart failure. Neurology. 2001;57:1986-1992.
16. Gunstad J, Paul RH, Cohen RA, Tate DF, Spitznagel MB, Gordon E. Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr Psychiatry. 2007;48:57-61.
17. Friedman JI, Wallenstein S, Moshier E et al. The effects of hypertension and body mass index on cognition in schizophrenia. Am J Psychiatry. 2010;167:1232-1239.
18. Guo X, Zhang Z, Wei Q, Lv H, Wu R, Zhao J. The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia. BMC Psychiatry. 2013;13:109.
19. Roher AE, Debbins JP, Malek-Ahmadi M et al. Cerebral blood flow in Alzheimer's disease. Vasc Health Risk Manag. 2012;8:599-611.
20. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64:598-604.
21. Funahashi H, Yada T, Suzuki R, Shioda S. Distribution, function, and properties of leptin receptors in the brain. Int Rev Cytol. 2003;224:1-27.